• The number of incident cases of AML in the countries under study will increase by 43%, from 58,000 to 82,000, in ten years.
  • Of the countries considered in this analysis, the incidence of AML is highest in Turkey at 2.4 per 100,000 per year.
  • Of all incident cases of AML, 25% have FLT3-ITD and 5% have FLT3-TKD/ disease.
  • The average age of all incident cases of AML in the countries under study is 54.

Table of contents

  • Acute Myeloid Leukemia - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • Overview
          • Diagnosed Incidence of Acute Myeloid Leukemia per 100,000 People of All Ages in 2019 and 2029
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Myeloid Leukemia over the Next Ten Years
          • Number of Additional Incident Cases of Acute Myeloid Leukemia Incurred Over 2019-2029 in the Countries Under Study
      • Epidemiology Data
      • Methods
        • Diagnosed Prevalent Cases
        • Diagnosed Incident Cases
        • FLT-3 Mutation
        • Lifetime DALYs Gained
        • Drug-Treatable Populations
        • Drug-Treated Populations
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Acute Myeloid Leukemia
          • Studies Excluded from the Analysis of Acute Myeloid Leukemia
        • Risk/Protective Factors
          • Risk/Protective Factors for Acute Myeloid Leukemia
        • Bibliography
        • Glossary

    Author(s): Pramilesh Tekchand Suryawanshi; Nishant Kumar, M.P.H.

    Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Before joining DRG, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.

    Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.


    Related Reports

    Acute Myeloid Leukemia - Landscape & Forecast - Disease Landscape & Forecast

    Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associat...

    View Details

    Acute Myeloid Leukemia - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)

    KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

    View Details

    Acute Myeloid Leukemia | Disease Landscape and Forecast | G7 | 2020

    Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from c...

    View Details

    Acute Myeloid Leukemia - Geographic Focus: China - Acute Myeloid Leukemia | China In-Depth | China

    Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historic...

    View Details